We are advancing multiple first-in-class and best-in class programs.
Giving each program the best path forward
We create asset-centric vehicles for the development of our internal pipeline of preclinical candidates or to accelerate breakthrough innovations coming from academia. These asset-centric companies benefit from dedicated teams and targeted investments for a focused development.
We build a strong pipeline using our drug discovery platforms to tackle brand new targets, challenging or orphan GPCRs considered intractable targets.